Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2B3-101 feasibility study in breast cancer with leptomeningeal metastases
NL-OMON39893Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin glutathione pegylated liposomal and trastuzumab in breast cancer and Carcinomatous Meningitis (CM) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Leptomeningeal metastasis response score. Planned start Aug 2013; status: not yet recruiting.
02
Drugs
doxorubicin glutathione pegylated liposomaltrastuzumab
03
Conditions
breast cancerCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on NL-OMON39893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39893.